Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis

Journal of Neuroimaging

Volumn 7, Issue 1, 1997, Pages 1-7

  Zhao, Guo Jun ^a   Li, David K B ^a   Wolinsky, Jerry S ^b   Koopmans, Robert A ^a   Mietlowski, William ^c   Redekop, William K ^a   Riddehough, Andrew ^a   Cover, Keith ^a   Paty, Donald W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TEXAS   (United States)

^c Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; OLIVE OIL; CYCLOSPORIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MONITORING; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; MAJOR CLINICAL STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; TREATMENT DURATION;

EID: 0008266721     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1111/jon1997711     Document Type: Article

References (19)

1. Compston ND. Disseminated sclerosis: assessment of the effect of treatment on the course of the disease. Lancet 1953; 2:271-275
2. Li DKB, Mayo J, Fache S, et al. Early experience in nuclear magnetic resonance imaging of multiple sclerosis. Ann NY Acad Sci 1984;436:483-486
3. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
4. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990;27:591-605
5. Koopmans RA, Li DKB, Redekop WK, et al. The use of magnetic resonance imaging in monitoring interferon therapy of multiple sclerosis. J Neuroimag 1993;3:163-168
6. Paty DW, Isaac CD, Grochowski E, et al. Magnetic resonance imaging (MRI) in multiple sclerosis (MS): a serial study in relapsing and remitting patients with quantitative measurements of lesion size. Neurology 1986;36(suppl 1):177 (Abstract)
7. Conover WJ, Iman RI. Analysis of covariance using the rank transformation. Biometrics 1982;38:715-724
8. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
9. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Arch Neurol 1989;46: 1107-1112
10. Willoughby EW, Grochowski E, Li DKB, et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989;25: 43-49
11. Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci 1988; 15:266-272
12. Paty DW, Koopmans RA, Zhao GJ, et al. Magnetic resonance imaging (MRI) as an outcome measure in multiple sclerosis. J Neurol Rehabil 1993;7:31-43
13. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
14. Koopmans RA, Li DKB, Zhao GJ, Paty DW. The prognostic value of MRI in multiple sclerosis. ASNR 31st Ann Meeting NY, NY 1993; (Abstract)
15. Filippi M, Horsfioel MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-641
16. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Beta-interferon 1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
17. Rao SM, Leo GJ, Haughton VM, et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989;39:161-166
18. Khoury SJ, Guttmann CRG, Orav FJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-2124
19. 2-weighted brain MRI activity in multiple sclerosis: a follow up study. Neurology 1995;45: 255-260